ICD-10-CM Billable Code

M32.15

Tubulo-interstitial nephropathy in systemic lupus erythematosus

Clinical Classification Guidelines

Medical Intelligence & Overview

Tubulo-interstitial nephropathy in systemic lupus erythematosus (SLE) is a kidney condition characterized by inflammation and damage to the tubules and interstitial tissue within the kidneys. This condition is a specific manifestation of SLE, an autoimmune disease where the immune system mistakenly attacks the body's own tissues. When SLE affects the kidneys, it can lead to impaired kidney function, which necessitates careful management and monitoring.

Causes & Symptoms

Clinical Causes: Autoimmune response: The body's immune system attacks kidney tissues, especially in SLE. Immune complex deposition: Abnormal immune complexes deposit in the kidney tissue, triggering inflammation. Genetic predisposition: Certain genetic factors may increase susceptibility. Environmental factors: Stress, infections, and certain medications can exacerbate kidney involvement in SLE.

Key Symptoms: Swelling in legs, ankles, or around the eyes due to fluid retention. Blood in the urine (hematuria). Foamy or dark-colored urine indicating protein loss. Fatigue and weakness resulting from decreased kidney function. High blood pressure (hypertension). Reduced urine output in more severe cases. Pain or tenderness in the back or sides. General symptoms of systemic lupus erythematosus, such as joint pain, skin rashes, and fever.

Diagnostic & Treatment

Diagnosis Path: Diagnosing tubulo-interstitial nephropathy in SLE involves a combination of clinical tests and procedures including: - Blood tests: To assess kidney function (creatinine, blood urea nitrogen) and detect immune activity. - Urinalysis: To identify protein, blood, or other abnormalities. - Imaging studies: Ultrasound or other imaging to evaluate kidney size and structure. - Kidney biopsy: A definitive test where a small tissue sample is examined under a microscope to confirm inflammation and damage specifics. - Serologic tests: Detection of specific autoantibodies associated with SLE, such as anti-dsDNA and anti-Smith antibodies.

Treatment Protocols: Managing tubulo-interstitial nephropathy in SLE focuses on controlling the underlying autoimmune activity and preserving kidney function: - Immunosuppressive medications: Corticosteroids and drugs like azathioprine or mycophenolate mofetil to reduce inflammation. - Blood pressure control: Use of antihypertensive agents, particularly ACE inhibitors or ARBs, which also protect kidney function. - Managing proteinuria: Medications to reduce protein loss and prevent progression. - Lifestyle modifications: Dietary adjustments, limiting salt intake, and avoiding nephrotoxic substances. - Regular monitoring: Frequent blood and urine tests to assess disease activity and kidney health. - Treatment of SLE: Addressing other aspects of lupus with appropriate therapies to control overall disease activity. In some cases, advanced interventions like dialysis or kidney transplantation may be necessary if kidney failure occurs.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is M32.15 a billable ICD-10 code?
Yes, M32.15 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report M32.15?
Clinical documentation must specify the nature of Tubulo-interstitial nephropathy in systemic lupus erythematosus and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Clinical Meta Tags

lupus systemic erythematosus nephropathy